U.S. FDA Approves QULIPTA® (atogepant) for Adults With Chronic Migraine

AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved expanding the indication of QULIPTA® (atogepant) for the preventive treatment of migraine in adults. The approval makes QULIPTA the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist approved to prevent episodic and chronic migraine.

The American Migraine Foundation is committed to helping people living with migraine learn about treatment options they need and deserve as they become available. Learn more in AbbVie’s full press release and remember to always talk to your doctor before changing your treatment plan.